Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from causing blood vessels to narrow. This blockade leads to vasodilation, reduced aldosterone release, and lower sodium‑water retention, which together lower systemic blood pressure.

The appropriate dose of Olmetec is determined by the prescribing clinician based on the patient’s blood pressure, kidney function, and overall health status. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions.

Olmesartan medoxomil is contraindicated in pregnancy because it can cause fetal toxicity and injury. It is also not recommended for breastfeeding mothers unless the benefits outweigh the risks, as limited data are available on excretion in breast milk.

To order Olmetec, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Olmetec belongs to the ARB class, which generally offers similar blood‑pressure‑lowering efficacy to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle.

Olmetec tablets should be stored below 25 °C in a dry place, protected from moisture and light. Keep the medication in its original container until use and discard any tablets that appear discoloured or damaged.

Olmetec is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious adverse reactions to Olmetec can include angio‑edema, severe hypotension, acute kidney injury, and hyperkalemia. Patients should seek immediate medical attention if they experience swelling of the face, lips or throat, dizziness, fainting, or a sudden change in urine output.

Olmetec should not be used by individuals who are pregnant, have known hypersensitivity to olmesartan or any ARB components, or have severe renal impairment without close monitoring. It is also avoided in patients taking aliskiren who have diabetes.